Company
Headquarters: Carlsbad, CA, United States
Founded: 1989
Employees: 660
CEO: Dr. Brett P. Monia Ph.D.
$6.84 Billion
USD as of July 1, 2025
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $309.91 B |
Vertex Pharmaceuticals Incorporated | $117.36 B |
CSL Limited | $95.75 B |
Regeneron Pharmaceuticals, Inc. | $59.14 B |
Marinomed Biotech AG | $58.56 B |
Company | Market Cap (USD) |
---|---|
Lilly | $699.59 B |
Johnson & Johnson | $374.29 B |
AbbVie | $336.94 B |
Novo Nordisk | $309.91 B |
UnitedHealth Group | $279.90 B |
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; Flamingo Therapeutics, Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Last Financial Reports Date | March 31, 2025 |
Revenue TTM | $717.3 M |
EBITDA | $-460,854,016 |
Gross Profit TTM | $-181,148,000 |
Profit Margin | -63.86% |
Operating Margin | -111.59% |
Quarterly Revenue Growth | 10.10% |
Ionis Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: IONS wb_incandescent
Stock: FSX: ISI wb_incandescent
nusinersen, inotersen, volanesorsen, plazomicin, mipomersen
Founder(s): Stanley T. Crooke
Brett P. Monia, CEO Elizabeth L. Hougen, CFO Joseph Loscalzo, Chairman of the Board